DexCom (NASDAQ:DXCM) Given “Buy” Rating at BTIG Research

BTIG Research reiterated their buy rating on shares of DexCom (NASDAQ:DXCM) in a research note issued to investors on Monday,Benzinga reports. They currently have a $85.00 target price on the medical device company’s stock.

Several other equities analysts have also commented on the company. Truist Financial reiterated a “buy” rating and issued a $80.00 target price (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. Barclays restated an “underweight” rating and issued a $72.00 price target (up from $71.00) on shares of DexCom in a report on Friday, February 13th. Mizuho increased their price objective on shares of DexCom from $78.00 to $90.00 and gave the stock an “outperform” rating in a report on Friday, February 13th. Wells Fargo & Company lowered their target price on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a report on Friday, February 13th. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $92.00 price target on shares of DexCom in a research report on Tuesday, December 16th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $85.18.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $68.74 on Monday. The company has a 50-day simple moving average of $70.72 and a 200-day simple moving average of $68.67. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59. The company has a market cap of $26.46 billion, a PE ratio of 32.73, a price-to-earnings-growth ratio of 1.32 and a beta of 1.48. DexCom has a 12 month low of $54.11 and a 12 month high of $89.98.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.03. The business had revenue of $1.26 billion for the quarter, compared to the consensus estimate of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The company’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.45 earnings per share. On average, equities analysts anticipate that DexCom will post 2.03 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Reflection Asset Management acquired a new position in DexCom during the 4th quarter worth approximately $25,000. Andra AP fonden purchased a new stake in shares of DexCom during the second quarter valued at approximately $26,000. Twin Peaks Wealth Advisors LLC purchased a new stake in shares of DexCom during the second quarter valued at approximately $26,000. SJS Investment Consulting Inc. lifted its position in shares of DexCom by 4,800.0% during the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after purchasing an additional 384 shares in the last quarter. Finally, Financial Consulate Inc. acquired a new position in shares of DexCom during the third quarter worth $29,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.